Erasca (ERAS) Expected to Release Quarterly Earnings on Wednesday

Erasca (NASDAQ:ERAS) is expected to announce its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Erasca to post earnings of ($0.1301) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Erasca (NASDAQ:ERAS) last announced its earnings results on Tuesday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). On average, analysts expect Erasca to post ($0.49) EPS for the current fiscal year and ($0.65) EPS for the next fiscal year.

Erasca Stock Up 4.2%

NASDAQ:ERAS opened at $14.64 on Wednesday. The firm has a market cap of $5.12 billion, a PE ratio of -15.41 and a beta of 0.68. Erasca has a 12 month low of $2.11 and a 12 month high of $24.28. The company’s 50-day moving average price is $15.35 and its two-hundred day moving average price is $15.04.

Analysts Set New Price Targets

ERAS has been the subject of several research analyst reports. Morgan Stanley lifted their price objective on Erasca from $12.00 to $21.00 and gave the company an “equal weight” rating in a research report on Monday, July 20th. HC Wainwright lifted their price objective on shares of Erasca from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Guggenheim increased their target price on Erasca from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Bank of America lifted their price target on Erasca from $18.00 to $20.00 and gave the company a “neutral” rating in a research note on Friday, August 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Erasca in a research report on Tuesday, September 8th. Eight investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Erasca has an average rating of “Moderate Buy” and a consensus target price of $22.09.

Erasca Company Profile

Erasca, Inc (NASDAQ: ERAS) is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with RAS/MAPK pathway-driven cancers. The company’s research and development programs are designed to target molecular alterations that contribute to tumor growth and treatment resistance, including mutations involving the RAS family of proteins and related signaling pathways.

Erasca’s pipeline has included small-molecule oncology candidates such as naporafenib, a pan-RAF inhibitor being studied in cancers with aberrant RAS/MAPK signaling, as well as additional investigational therapies intended to address difficult-to-treat oncogenic drivers.